Digital Diabetes Management Market, Application, Specification Analysis, Size and Growth 2022 To 2027

According to the new market research report "Digital Diabetes Management Market by Product (Device (Smart Glucometer, CGM, Insulin Patch Pump), Diabetes Apps, Service, Data Management Software), Device Type (Handheld & Wearables), End User (Hospitals & Self/home healthcare) - Global Forecast to 2027", MarketsandMarkets expects the global digital diabetes management market is projected to reach USD 25.5 Billion by 2027 from an estimated USD 14.3 Billion in 2022, at a CAGR of 12.2% during the forecast period

Browse in-depth TOC on "Digital Diabetes Management Market"
199 - Tables
54 - Figures
234 - Pages

Scope of the Report:

Report Coverage Details
Market Size USD 25.5 Billion by 2027
CAGR 12.2%
Historical Data 2020-2027
Base Year 2021
Forecast Period 2022-2027
Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered By Product & Services, By Type, By End User and By Region
Geographies Covered North America

  • US
  • Canada

  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
Asia Pacific

  • Japan
  • China
  • India
  • Australia
  • Rest of APAC
Latin America

  • Brazil
  • Mexico
  • Rest of LATAM
Middle East and Africa
Key Companies Profiled/Vendors Medtronic (Ireland), B. Braun Melsungen AG (Germany), Dexcom, Inc. (US), Abbott Laboratories (US), F. Hoffmann-La Roche (Switzerland), Insulet Corporation (US), Tandem Diabetes Care (US), Ascensia Diabetes Care Holdings AG (Switzerland), LifeScan, Inc. (US), Tidepool (US), AgaMatrix (US), Glooko, Inc. (US), DarioHealth Corporation (Israel), One Drop (US), Dottli (Finland), Ypsomed Holding AG (Switzerland), ARKRAY (Japan), ACON Laboratories, Inc. (US), Care Innovations, LLC (US), Health2Sync (Taiwan), Emperra GmbH E-Health Technologies (Germany), Azumio (US), Decide Clinical Software GmbH (Austria), Pendiq GmbH (Germany), and BeatO (India) among others.
Key Market Opportunities Increasing diabetes-related health expenditure
Key Market Drivers Increasing prevalence of diabetes

The rising prevalence of diabetes has increased the focus on the development and adoption of better solutions for diabetes care. Also, advancements in technologies have ensured the introduction of highly flexible solutions in the market. The increasing adoption of cloud-based enterprise solutions and the growing use of connected devices and apps are some of the other major factors supporting market growth. However, factors such as the high device costs, lack of reimbursement in developing countries, and the higher acceptance of traditional diabetes management devices are expected to restrain the growth of this market during the forecast period.

In this report, the digital diabetes management market is segmented on the basis of product & services, type, end user, and region.

Various products and services included in the digital diabetes management market are devices, apps, data management software & platforms, and services. The devices segment comprises smart glucose meters, continuous glucose monitoring (CGM) systems, smart insulin pens, and smart insulin pumps/closed-loop systems & smart insulin patches. Similarly, the apps segment is further categorized into diabetes & blood glucose tracking apps and obesity & diet management apps. The devices segment accounted for the largest share of 74.4% of the digital diabetes management market in 2021. Factors such as the increasing demand for wireless and wearable devices for diabetes management, growing acceptance of smart insulin pumps & pens for insulin delivery, and the growing awareness about continuous glucose monitoring in patients are driving the market growth.

Different types of digital diabetes management device studied in the report are handheld devices and wearable devices. Among these, the wearable devices accounted for the largest share of 60.3% of the digital diabetes management devices market in 2021. This segment is projected to reach USD 12,029.9 million by 2027 from USD 6,470.1 million in 2022. Factors such as the increasing number of regulatory approvals for CGM systems; technological advancements such as closed-loop pump systems, smart insulin patches, and other pipeline devices; and the growing adoption of smart insulin pumps and insulin patches for self-insulin delivery in diabetes management are boosting the segment growth.

Various end users of the digital diabetes management market are self/home healthcare, hospitals & specialty diabetes clinics, and academic & research institutes. The self/home healthcare accounted for the largest share of 74.5% of the digital diabetes management market in 2021. The large share of this segment can mainly be credited to technological advancements and a shift toward home care and self-management of diabetes.

Geographical Growth Scenario:

North America is estimated to grow at the highest CAGR during the forecast period. The region also accounted for the largest market share of 41.4%, followed by Europe with a share of 29.0% in 2021. Various factors attributing to the growth of the digital diabetes management market in North America are growing adoption of connected diabetes management devices, high adoption of diabetes management apps, growing demand for integrated hybrid closed-loop systems, favorable reimbursement policies, and government initiatives to promote digital health in the region.

Furthermore, In Asia Pacific, countries such as China and India have a high prevalence rate of diabetes, primarily due to the increasing urbanization, population and lifestyle changes. The increasing incidence of diabetes, rising awareness, high undiagnosed population, and the rising penetration of smartphones and tablets have propelled the adoption of digital diabetes management solutions in the region.

Key Players:

Prominent players in the Electrophysiology market include Abbott (US), Medtronic (Ireland), Boston Scientific Corporation (US), Koninklijke Philips N.V. (Netherlands), GE Healthcare (US), Siemens Healthcare GmbH (Germany), Stereotaxis, Inc. (US), Merit Medical Systems (US), Atricure Inc. (US), APN Health, LLC (US), Osypka Medical (Germany), Japan LifeLine Co., Ltd. (Japan), Johnson & Johnson (US), Biotronik (Germany), MicroPort Scientific Corporation (China), and Acutus Medical, Inc. (US), and Among others